This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmAthene Presents SparVaxA® Anthrax Vaccine Data At The New Technologies New Vaccines 2014 Conference

ANNAPOLIS, Md., April 1, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax ® next-generation anthrax vaccine program were recently presented at the 8 th Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's achievements in developing key analytical assays which are being employed to monitor the stability and potency of SparVax ®.

"We believe SparVax ® is a promising alternative to the current anthrax vaccine and other rPA-based vaccines due, in part, to its unique formulation.  This formulation, and our development of newer, more precise assays have facilitated the development and testing of a vaccine product with enhanced stability and potency," said Dr. Powell. "Further, our research has demonstrated that subtle changes in the interaction between rPA and an immune-stimulating adjuvant (Alhydrogel ®) yield important improvements in stability and immunogenicity."

Data presented by Dr. Powell show how the addition of phosphate alters the surface chemistry of the immune-stimulating adjuvant, Alhydrogel ® in such a way that the stability profile of rPA is improved and potency is increased, as compared to vaccine formulations with less phosphate. In addition, the phosphate/Alhydrogel ® formulation demonstrated five-fold higher potency than a comparable low phosphate formulation, as tested in the prior mouse challenge assay.

The need for newer anthrax vaccines based on modern vaccine technology, which offer the potential for improved safety, convenience and cost-effectiveness, is widely acknowledged.  SparVax ® is a next-generation anthrax vaccine being developed for pre- and post-exposure protection against anthrax.  It is based on recombinant protective antigen (rPA), the principal virulence factor of the bacterial organism, B. anthracis (anthrax).

PharmAthene's rPA anthrax vaccine program has been supported by funding from the National Institute of Allergy and Infectious Disease, National Institutes of Health, and the Biomedical Advanced Research and Development Authority.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.20 -2.10%
TSLA $247.71 -1.50%
YHOO $36.58 -1.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs